AI drug discovery deals move to fund structures and paired data workflows

These deals give biotech founders capital and access to validation platforms. They do not have to wait on a single large pharma partner. For pharma buyers, the promise is earlier evidence on whether a target and a molecule work. Neither company has said how much the QurieGen and Rayca pilot is worth.

Insilico turns to a fund structure

The fund is named Insilico Pudong Value Partners (Shanghai) Private Investment Fund Partnership. The company's subsidiaries Insilico Medicine Shanghai and Insilico Pudong signed the partnership agreement with Value Partners Shenzhen, Pudong Construction and Hanchen Lanxi. The fund targets up to CNY 1.01 billion, about $151.6 million. It will invest in growth-stage biopharma, life sciences and AI companies from Series A through pre-IPO. Insilico said the vehicle will not become a subsidiary. It will not consolidate the vehicle's financial results into the group's accounts. The company framed the participation as access to growth opportunities in biopharma and life sciences.

Insilico is an AI-driven drug discovery company. Value Partners Shenzhen is an asset manager. Pudong Construction is an infrastructure investor. Hanchen Lanxi's role remains unspecified.

QurieGen and Rayca connect discovery and design

QurieGen and Rayca Precision announced a joint drug discovery workflow. It links target discovery, AI-powered molecular design and cellular validation in one loop.

QurieGen uses a time-resolved single-cell multi-omics platform that measures gene expression, surface and intracellular proteins, and phosphoproteins in individual cells over time. Rayca models how proteins move and change shape, including binding sites that are only temporarily accessible. It combines AI with physics-based simulations to design molecules. Selected molecules are synthesized and tested in disease-relevant cellular models. The results feed the next design cycle. QurieGen measures molecular and cellular changes to check whether a molecule produces the intended biological response. The companies said a pilot begins with one biological question, a disease area and agreed constraints. The companies did not disclose financial terms.

Why validation is the bottleneck

Drug development remains heavily focused on established targets, according to the two companies. Insufficient efficacy is still a major reason candidates fail in clinical development, they said. Target discovery, molecular design and experimental validation usually happen in separate stages. Parse Biosciences and Nomic Bio are attacking a similar data problem with Cascade. The dataset will combine 100 million single-cell RNA-seq profiles with more than 11,000 secretory protein profiles, the companies say. It will also aggregate responses to more than 150,000 individual and combined cytokine and drug conditions. The sequencing work runs at Parse's GigaLab. The company says GigaLab can analyse billions of cells annually. Nomic's Omini 1000 platform measures more than 1,000 secreted proteins across samples.

According to the companies, five named partners have signed on: GSK, Pfizer, Sanofi, Graph Therapeutics and Turbine.

Data scale and capital

Vitroscope is a biotech building perfusion platforms for living tissue. It raised $7 million: a $5 million seed round and $2 million in non-dilutive funding from the Research Council of Norway. Cerberus Ventures and YZR Capital co-led the seed round. The company has raised $8.8 million to date. Its vitro.alive benchtop platform runs six independent, parallel experiments with programmable perfusion and live-cell imaging. The in-development vitro.scale is designed for 96 parallel experiments. Vitroscope and Instant Bio kept vascularised human brain organoids under perfusion for seven days with vitro.alive, the company says.

3billion will present its AI drug discovery strategy at BIO-Europe 2026. The strategy draws on genomic data from more than 120,000 patients and over 600,000 clinical case records. The conference runs 9-11 November in Cologne. It is expected to attract more than 6,000 industry professionals.

3billion studies people who carry disease-causing variants but stay asymptomatic. The aim is to find genetic modifiers that affect disease onset and severity. It also uses AI to find previously unexplored binding sites on proteins that have traditionally been difficult to target.

What happens next

3billion plans partnering meetings at BIO-Europe 2026 to explore joint research and drug development deals. The QurieGen and Rayca pilot starts with one biological question and a disease area. The companies did not disclose a timeline. Insilico said the fund has yet to complete its establishment procedures. Its actual investment targets and pace remain undisclosed.